Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loteprednol Etabonate Ointment for Post-Cataract Surgery Inflammation
NCT00645671Phase 3Completed
- Sponsor
- Bausch + Lomb
- Start
- Mar 2008
- Primary completion
- Mar 2009
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of loteprednol etabonate ophthalmic gel 0.38% in ocular inflammation (2 arms), sponsored by Bausch + Lomb. Primary endpoints: Complete Resolution of Anterior Chamber Cells and Flare at 8 days and Grade 0 for Pain at 8 days. Started Mar 2008; status: completed.
02
Drugs
loteprednol etabonate ophthalmic gel 0.38%
03
Conditions
ocular inflammation
Beyond the preview
Go deeper on NCT00645671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00645671.